Group 1 - Three new healthcare-themed funds were launched on January 21, with fundraising amounts of 168 million, 75.87 million, and 10.01 million RMB respectively [1] - The launch of these funds indicates a growing interest among public fund institutions in the healthcare sector, with several firms filing for similar funds this year [1] - The advantages of the initiator funds include lower fundraising thresholds and a tighter alignment of interests between fund managers and investors, which can enhance management effectiveness [1] Group 2 - The healthcare sector has shown significant internal performance differentiation, with innovative drugs and export-related industries achieving notable excess returns [2] - Fund managers maintain an optimistic outlook for the healthcare industry, anticipating a gradual recovery in overall revenue growth by 2026, with a focus on innovative drug supply chains and medical outsourcing [2] - The innovative drug sector is transitioning from rapid imitation to differentiated innovation, with a marked increase in overseas licensing transactions by domestic pharmaceutical companies since 2020 [2] Group 3 - Investment strategies in the healthcare sector for 2026 will focus on innovation upgrades and domestic demand improvements [3] - The innovative drug and device investment opportunities are expected to continue, but investors will seek greater certainty, making stock selection more critical [3] - The traditional Chinese medicine sector is currently undervalued, presenting long-term investment potential, while certain segments of consumer healthcare and medical devices are beginning to recover [3]